• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing Arcutis Biotherapeutics (ARQT) Valuation After Positive ZORYVE Infant Phase 2 Trial Results

    Simply Wall St·04/01/2026 21:24:03
    Listen to the news

    Arcutis Biotherapeutics (ARQT) is back in focus after new INTEGUMENT-INFANT Phase 2 data on ZORYVE cream 0.05% in infants with mild to moderate atopic dermatitis, supporting a planned supplemental New Drug Application.

    See our latest analysis for Arcutis Biotherapeutics.

    The new clinical data arrives after a mixed stretch for the shares, with a 1-day share price return of 10.45% and 7-day share price return of 7.92% contrasting with a 30-day share price return decline of 12.64%. However, a 1-year total shareholder return of 57.28% and 3-year total shareholder return of 118.55% point to stronger momentum over a longer horizon.

    If this kind of pipeline news has your attention, it could be a good moment to look at other immunology and dermatology names through our healthcare AI opportunities screener, starting with 34 healthcare AI stocks.

    With Arcutis valued at about US$2.6b, trading at US$23.56 and sitting at a sizeable discount to both analyst targets and intrinsic estimates, the key question now is whether this is a genuine opportunity or if the market is already pricing in future growth.

    Most Popular Narrative: 41.1% Undervalued

    Compared with the last close at $23.56, the most followed narrative puts Arcutis Biotherapeutics’ fair value at $39.99. This implies a wide valuation gap that hinges heavily on ZORYVE and its growth path.

    It is almost impossible to obtain a drug label from the FDA for pediatric use, this topical non steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.

    Read the complete narrative.

    Curious what kind of revenue ramp, profit margins and eventual earnings multiple are baked into that $39.99 fair value, according to Coward_Nutlick? The narrative leans on accelerating earnings, a shift to profitability and a terminal valuation that is usually seen in larger, established biopharma names. However, the exact assumptions sit under the surface waiting to be unpacked.

    Result: Fair Value of $39.99 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, investors still face execution risk around broader ZORYVE adoption, as well as the possibility that competition or pricing pressure could limit the sizeable opportunity implied in this bullish narrative.

    Find out about the key risks to this Arcutis Biotherapeutics narrative.

    Next Steps

    With sentiment split between opportunity and risk, this is a good time to check the numbers yourself and move quickly from headline to detail by weighing the 5 key rewards and 1 important warning sign.

    Ready for more investment ideas?

    If you stop at a single stock, you risk missing other opportunities that better fit your goals, risk comfort and time horizon, so keep your watchlist evolving.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.